Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bayer, Nektar Join For Inhaled Drug
August 13, 2007
| A version of this story appeared in
Volume 85, Issue 33
Bayer HealthCare and Nektar Therapeutics will develop an inhalable version of the aminoglycoside antibiotic amikacin, using Nektar's drug delivery technology. The compound is in Phase II clinical trials for treating ventilated patients with hospital-acquired gram-negative pneumonias, which cause a significant number of deaths. Nektar will receive $50 million up-front and possibly another $125 million if milestones are met. Bayer will handle clinical development and manufacturing. The partners will copromote the product in the U.S. and share profits; Nektar will receive royalties on non-U.S. sales.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X